Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $153,126 - $170,064
1,800 Added 9.0%
21,800 $1.93 Million
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $988,152 - $1.14 Million
11,400 Added 132.56%
20,000 $1.73 Million
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $535,214 - $715,347
6,100 Added 244.0%
8,600 $836,000
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $5.58 Million - $7.5 Million
-69,000 Reduced 96.5%
2,500 $258,000
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $5.87 Million - $6.93 Million
71,500 New
71,500 $6.06 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $973,068 - $1.21 Million
13,100 Added 64.85%
33,300 $2.57 Million
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $1.45 Million - $1.85 Million
20,200 New
20,200 $1.79 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.